Registry Study of Revcovi Treatment in Patients With ADA-SCID
The objective of this study is to develop a registry of patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) treated with Revcovi™ that contains clinical and biochemical assessments for safety and dose adjustment based on adenosine deaminase (ADA) activity and erythrocyte deoxyadenosine nucleotide (dAXP) levels as well as immunologic monitoring.
- Patients with diagnosis of ADA-SCID who require ERT with ADA as judged by the treating physicians, based on the medical history, biochemical test or genotyping.
- Understanding and willing to comply with the Registry recommendations via signed and dated written informed consent/assent.
- ADA-SCID patient requiring Revcovi as an ERT.
- Any condition that, in the opinion of the Investigator, makes the patient unsuitable for the study.